Related Experiment Videos
Immunologic manipulation for the threatened fetus.
1Department of Immunopathology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Australia. elizab@westgate.wh.usyd.edu.au
Thrombosis Research
|October 28, 2004
Summary
Antiphospholipid syndrome (APLS) in pregnancy is managed with aspirin and heparin, reducing pregnancy loss by 40%. Further immunologic therapies are needed for women who do not deliver a live infant.
Area of Science:
- Obstetrics and Gynecology
- Immunology
- Rheumatology
Background:
- Antiphospholipid syndrome (APLS) is a significant cause of recurrent pregnancy loss.
- Current management with low-dose aspirin and heparin has improved outcomes but is not universally successful.
Purpose of the Study:
- To review current management strategies for pregnant women with APLS.
- To explore novel immunomodulatory therapies for APLS patients who fail standard treatment.
Main Methods:
- Review of existing literature on APLS management in pregnancy.
- Discussion of emerging immunotherapies, including intravenous immunoglobulin, plasma exchange, and biologics.
Main Results:
- Low-dose aspirin and heparin therapy reduce pregnancy loss by 40% in APLS patients.
- A subset of APLS patients still experience pregnancy loss despite standard therapy.
Conclusions:
- While aspirin and heparin improve outcomes, further immunologic interventions are necessary for some APLS patients.
- Investigational therapies like monoclonal antibodies and biologics show promise for refractory APLS in pregnancy.